Vitamin D and Lung Function Decline in Adults With Asthma: The HUNT Study.

Vitamin D and Lung Function Decline in Adults With Asthma: The HUNT Study.

Am J Epidemiol. 2016 Mar 18;

Authors: Brumpton BM, Langhammer A, Henriksen AH, Camargo CA, Chen Y, Romundstad PR, Mai XM

Abstract
We investigated whether low 25-hydroxyvitamin D (25(OH)D) levels were associated with more lung function decline in adults with asthma and whether this association was modified by smoking status or inhaled corticosteroid (ICS) use. We analyzed data on 395 adults with asthma from the Nord-Trøndelag Health Study (1995-2008), Norway. Plasma 25(OH)D and lung function were measured at baseline, and lung function measurements were repeated at follow-up, approximately 11 years later. Linear regression was used to estimate lung function decline. Participants with low 25(OH)D (<50 nmol/L) had more decline in lung function measurements for forced expiratory volume in 1 second (FEV1) (388 mL), forced vital capacity (298 mL), and the FEV1/forced vital capacity ratio (3.7%) over the follow-up, compared with those with high 25(OH)D (?50 nmol/L) who declined 314 mL, 246 mL, and 3.0%, respectively (P = 0.08, 0.30, and 0.23, respectively). The associations were stronger in never smokers and non-ICS users. In never smokers, low 25(OH)D levels were associated with more decline in FEV1 (445 vs. 222 mL) (P = 0.01). In non-ICS users, low 25(OH)D levels were associated with more decline in FEV1 (467 vs. 320 mL) (P = 0.02). Low serum 25(OH)D levels were weakly associated with more lung function decline in adults with asthma, and stronger associations were observed in never smokers and non-ICS users.

PMID: 26994061 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents – Business Wire (press release)

SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Business Wire (press release)
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a …

and more »

View full post on asthma – Google News

SPIRIVA ® RESPIMAT ® Now Available in the US for Maintenance Treatment of Asthma in Adults and Adolescents – Business Wire (press release)

SPIRIVA ® RESPIMAT ® Now Available in the US for Maintenance Treatment of Asthma in Adults and Adolescents
Business Wire (press release)
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a …
SPIRIVA RESPIMAT Now Available in the US for Maintenance Treatment of Asthma in Adults and AdolescentsThe FINANCIAL

all 2 news articles »

View full post on asthma – Google News

SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents – PR Newswire (press release)

SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
PR Newswire (press release)
RIDGEFIELD, Conn., Feb. 3, 2016 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma in U.S. pharmacies. The U.S. Food and Drug …

and more »

View full post on asthma – Google News

Asthma exacerbation within 1 year predicts future exacerbation in children adults – Healio

Asthma exacerbation within 1 year predicts future exacerbation in children adults
Healio
“Because most patients with asthma in the United States do not have well-controlled asthma, identification of risk factors for asthma exacerbations in this population has the potential to guide treatment decisions and decrease asthma morbidity and

View full post on asthma – Google News